The Latest From CureMatch
A recent CureMatch case study was described in Hatch magazines “Startup Buzz” feature. Click here to read more.
Study suggests that genomic profiling may help identify risk for hyper-progression after immunotherapy SAN DIEGO, CA – May 4, 2017 – UCSD oncologist and CureMatch Co-Founder Dr. Razelle Kurzrock and colleagues have published a study in the journal Clinical Cancer Research investigating “hyper-progressors.” Hyper-progressors are patients who unexpectedly fail immunotherapy treatment within 2 months, while also experiencing rapid […]
April 28, 2017 – KUSI News featured CureMatch in its weekly segment “Healthy Living.” Anchor Sandra Mass discusses the benefits of CureMatch’s personalized approach to cancer therapy, and interviews CureMatch co-founders Blaise Barrelet and Dr. Razelle Kurzrock. CureMatch, the UCSD Moores Cancer Center, and the San Diego Supercomputer Center are all highlighted in the segment.
An article appeared in today's Coast News which chronicles Blaise Barrelet's journey from cancer patient to CureMatch CEO, and shares that the CureMatch personalized medicine approach is online and ready. Actionable insights based upon genomics are now available to the best oncologists across the country to quickly match up combination drug treatments using the most in-depth custom curated databases of drugs and cancer mutations available.
Phil Trubey, founder of the successful computer security company WebSense (now ForcePoint), has written an op-ed in the Rancho Santa Fe Post entitled “Got Cancer? Try CureMatch.” The article discusses the benefits of personalized medicine and the CureMatch report.
